Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02977143
Other study ID # 1609-101-793
Secondary ID
Status Completed
Phase N/A
First received November 27, 2016
Last updated April 1, 2018
Start date November 2016
Est. completion date March 2017

Study information

Verified date April 2018
Source Seoul National University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In urologic robotic surgery with steep Trendelenburg position, maintenance of cardiac preload and cardiac output is important for clinical prognosis. Previous studies reported the positive end-expiratory pressure (PEEP)-induced increase in central venous pressure (CVP) could be a accurate predictor of fluid responsiveness in cardiac surgical patients. The authors attempt to evaluate the predictability of PEEP-induced increase in CVP as well as stroke volume variation in urologic robotic surgery with Steep Trendelenburg position.


Description:

In urologic robotic surgery with steep Trendelenburg position, maintenance of cardiac preload and cardiac output is important for clinical prognosis. As a preload index, the predictability of central venous pressure, pulse pressure variation and stroke volume variations may be impaired due to the impaired hemodynamics that result from the effect of increased abdominal pressure and decreased venous return. Previous studies reported the positive end-expiratory pressure (PEEP)-induced increase in central venous pressure (CVP) could be a accurate predictor of fluid responsiveness in cardiac surgical patients. Therefore, the authors attempt to evaluate the predictability of PEEP-induced increase in CVP as well as stroke volume variation in urologic robotic surgery with Steep Trendelenburg position.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date March 2017
Est. primary completion date March 2017
Accepts healthy volunteers No
Gender Male
Age group 20 Years and older
Eligibility Inclusion Criteria:

- Adult patient undergoing robot-assisted laparoscopic radical prostatectomy or cystectomy.

- American Society of Anesthesiologist Physical Status Classification of 1, 2 or 3.

Exclusion Criteria:

- Medical history of arrhythmia or new-onset arrhythmia after anesthesia induction.

- Valvular or ischemic heart disease or left ventricular ejection fraction less than 40%.

- Any significant pulmonary disease or history of chronic obstructive pulmonary disease

- End-stage renal disease or preoperative creatinine > 1.4 mg/dl

Study Design


Intervention

Procedure:
Fluid loading of volulyte 300 ml
Administration of volulyte 300 ml and measurement of increase in cardiac index

Locations

Country Name City State
Korea, Republic of Seoul National University Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
Seoul National University Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary fluid responsiveness fluid responsiveness is determined when increase in cardiac index is more than 10% 5 minutes after administration of 300 ml volulyte
Secondary central venous pressure T1: baseline measurement of central venous pressure with positive end-expiratory pressure of zero one hour after the initiation of pneumoperitoneum
Secondary cardiac index T1: baseline measurement of cardiac index with positive end-expiratory pressure of zero one hour after the initiation of pneumoperitoneum
Secondary stroke volume variation T1: baseline measurement of stroke volume variation with positive end-expiratory pressure of zero one hour after the initiation of pneumoperitoneum
Secondary abdominal pressure T1: baseline measurement of abdominal pressure with positive end-expiratory pressure of zero one hour after the initiation of pneumoperitoneum
Secondary central venous pressure T2: measurement of positive end-expiratory pressure-induce increase in central venous pressure 5 minutes after the application of positive end-expiratory pressure of 10 cmH2O
Secondary cardiac index T2: measurement of cardiac index 5 minutes after the application of positive end-expiratory pressure of 10 cmH2O
Secondary stroke volume variation T2: measurement of stroke volume variation 5 minutes after the application of positive end-expiratory pressure of 10 cmH2O
Secondary abdominal pressure T2: measurement of abdominal pressure 5 minutes after the application of positive end-expiratory pressure of 10 cmH2O
Secondary central venous pressure T3: second baseline measurement of central venous pressure with positive end-expiratory pressure of zero 5 minutes after removal of positive end-expiratory pressure
Secondary cardiac index T3: second baseline measurement of cardiac index with positive end-expiratory pressure of zero 5 minutes after removal of positive end-expiratory pressure
Secondary stroke volume variation T3: second baseline measurement of stroke volume variation with positive end-expiratory pressure of zero 5 minutes after removal of positive end-expiratory pressure
Secondary abdominal pressure T3: second baseline measurement of abdominal pressure with positive end-expiratory pressure of zero 5 minutes after removal of positive end-expiratory pressure
Secondary central venous pressure measurement of central venous pressure after fluid administration T4: 5 minutes after administration of volulyte 300 ml
Secondary cardiac index measurement of cardiac index after fluid administration T4: 5 minutes after administration of volulyte 300 ml
Secondary stroke volume variation measurement of stroke volume variation after fluid administration T4: 5 minutes after administration of volulyte 300 ml
Secondary abdominal pressure measurement of abdominal pressure after fluid administration T4: 5 minutes after administration of volulyte 300 ml
Secondary arterial oxygen partial pressure (mmHg) arterial blood gas analysis 5 minutes after anesthesia induction
Secondary arterial carbon dioxide partial pressure (mmHg) arterial blood gas analysis 5 minutes after anesthesia induction
Secondary arterial oxygen partial pressure (mmHg) arterial blood gas analysis 1 minutes after the application of positive end-expiratory pressure of 10 cmH2O
Secondary arterial carbon dioxide partial pressure (mmHg) arterial blood gas analysis 1 minutes after the application of positive end-expiratory pressure of 10 cmH2O
Secondary arterial oxygen partial pressure (mmHg) arterial blood gas analysis 1 minutes after the start of skin closure
Secondary arterial carbon dioxide partial pressure (mmHg) arterial blood gas analysis 1 minutes after the start of skin closure
See also
  Status Clinical Trial Phase
Completed NCT03982095 - Survey on Lifestyle, Perceived Barriers and Development of Change in Patients With Prostate Cancer
Recruiting NCT05667636 - Early Salvage Stereotactic Radiotherapy for Biochemical Failure After RP Phase 2
Terminated NCT01996696 - Prevention of Metabolic Syndrome and Increased Weight Using Metformin Concurrent to Androgen Deprivation Therapy and Radiotherapy for Locally Advanced Adenocarcinoma of the Prostate Phase 2
Completed NCT01431391 - Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer Phase 2
Completed NCT03289130 - Dietary Factors and Racial Disparities in Prostate Cancer Aggressiveness
Recruiting NCT04462926 - Evaluation of Diagnostic Accuracy of [68Ga]Ga-PSMA-11 PET/CT in Primary Staging of Intermediate and High Risk Prostatic Cancer in Men Newly Diagnosed N/A
Completed NCT00001446 - A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer Phase 2
Completed NCT02729103 - Treatment Patterns in Metastatic Prostate Cancer N/A
Completed NCT00956228 - Study of Radioimmunoguided Intensity Modulated Radiotherapy (IMRT) for Prostate Cancer Phase 1/Phase 2
Completed NCT00126854 - High Field Magnetic Resonance Spectroscopy Imaging for Follow Up of Prostate Cancer Post Brachytherapy Implantation N/A
Completed NCT00247312 - Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial Phase 3
Completed NCT00174863 - Evaluation of SR 31747A Versus Placebo in Androgen-Independent Non Metastatic Prostate Cancer Phase 2
Terminated NCT04221828 - Trial of NanoPac Focal Therapy for Prostate Cancer Phase 2
Completed NCT00001266 - A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma Phase 2
Active, not recruiting NCT03935282 - Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors N/A
Completed NCT03693742 - MSG Use With 18F-DCFPyL PET/CT Imaging N/A
Recruiting NCT06236789 - Observation Study to Evaluate the Efficacy and Safety of Ifosfamide/Mesna in Patients With Metastatic Castration-resistant Prostate Cancer
Completed NCT02966535 - The Effect of Prolonged Inspiratory Time on Gas Exchange During Robot-assisted Laparoscopic Surgery With Steep Trendelenburg Position : A Crossover Randomized Clinical Trial N/A
Completed NCT00252460 - CT/MRI Co-registration Prostate Cancer Phase 1
Completed NCT04398173 - Detection Rate of Prostate Cancer in Men Undergoing MRI